- Home
- PROK vs LCNB Comparison
PROK vs LCNB Comparison
Compare PROK & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- LCNB
- Stock Information
- Founded
- PROK 2015
- LCNB 1877
- Country
- PROK United States
- LCNB United States
- Employees
- PROK N/A
- LCNB N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- LCNB Major Banks
- Sector
- PROK Health Care
- LCNB Finance
- Exchange
- PROK Nasdaq
- LCNB Nasdaq
- Market Cap
- PROK 220.6M
- LCNB 212.3M
- IPO Year
- PROK N/A
- LCNB N/A
- Fundamental
- Price
- PROK $1.70
- LCNB $16.84
- Analyst Decision
- PROK Buy
- LCNB
- Analyst Count
- PROK 5
- LCNB 0
- Target Price
- PROK $4.50
- LCNB N/A
- AVG Volume (30 Days)
- PROK 437.3K
- LCNB 22.1K
- Earning Date
- PROK 11-12-2024
- LCNB 10-21-2024
- Dividend Yield
- PROK N/A
- LCNB 5.23%
- EPS Growth
- PROK N/A
- LCNB N/A
- EPS
- PROK N/A
- LCNB 0.52
- Revenue
- PROK N/A
- LCNB $74,686,000.00
- Revenue This Year
- PROK N/A
- LCNB N/A
- Revenue Next Year
- PROK N/A
- LCNB $15.49
- P/E Ratio
- PROK N/A
- LCNB $32.35
- Revenue Growth
- PROK N/A
- LCNB 3.03
- 52 Week Low
- PROK $1.12
- LCNB $12.42
- 52 Week High
- PROK $4.44
- LCNB $17.27
- Technical
- Relative Strength Index (RSI)
- PROK 43.50
- LCNB 63.48
- Support Level
- PROK $1.95
- LCNB $15.95
- Resistance Level
- PROK $2.27
- LCNB $17.24
- Average True Range (ATR)
- PROK 0.18
- LCNB 0.36
- MACD
- PROK 0.03
- LCNB 0.06
- Stochastic Oscillator
- PROK 26.45
- LCNB 80.37
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.